Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046517 | 0.80 | L3MBTL1 (0.60) | SIGMAR1ESR1L3MBTL1S1PR2S1PR1 | |
| SCHEMBL18591716 | 0.79 | ESR1 (0.44) | SIGMAR1ESR1L3MBTL1MMP8 | |
| SCHEMBL21367140 | 0.72 | MAOA (0.54) | SIGMAR1ESR1 | |
| SCHEMBL1609925 | 0.72 | ESR1 (0.48) | SIGMAR1ESR1S1PR1S1PR3MMP8 | |
| SCHEMBL1611760 | 0.71 | ESR1 (0.47) | ESR1S1PR1S1PR3 | |
| SCHEMBL1611536 | 0.71 | ESR1 (0.47) | ESR1S1PR1S1PR3 | |
| SCHEMBL1611580 | 0.71 | ESR1 (0.47) | ESR1S1PR1S1PR3 | |
| SCHEMBL24419594 | 0.71 | ESR1 (0.47) | SIGMAR1ESR1L3MBTL1MMP8 | |
| SCHEMBL26569953 | 0.70 | ESR1 (0.56) | ESR1S1PR1S1PR3 | |
| SCHEMBL1612101 | 0.70 | ESR1 (0.50) | SIGMAR1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | SIGMAR1 4030/4885ESR1 1132/4885L3MBTL1 1880/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | SIGMAR1 4030/4885ESR1 1132/4885L3MBTL1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.